Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure: A double-blind, placebo-controlled trial

Journal of the American College of Cardiology

Volumn 56, Issue 21, 2010, Pages 1701-1708

  Cice, Gennaro ^a   Di Benedetto, Attilio ^b   D'Isa, Salvatore ^a,c   D'Andrea, Antonello ^a   Marcelli, Daniele ^d   Gatti, Emanuele ^d   Calabr, Raffaele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NephroCare Italy   (Italy)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

^d FRESENIUS MEDICAL CARE   (Germany)

Author keywords

chronic heart failure; dialysis; mortality; telmisartan

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTITHROMBOCYTIC AGENT; CARVEDILOL; DIGITALIS; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PLACEBO; POTASSIUM; RAMIPRIL; TELMISARTAN;

ADULT; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DIARRHEA; DISEASE CLASSIFICATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; FLUSHING; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SORE THROAT; SURVIVAL TIME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; ITALY; LENGTH OF STAY; MALE; MIDDLE AGED; MORBIDITY; PROSPECTIVE STUDIES; RENAL DIALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 78349252300     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.03.105     Document Type: Article

References (30)

1. B.D. Schreiber Congestive heart failure in patients with chronic kidney disease and on dialysis Am J Med Sci 352 2003 179 193
2. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
3. R. Garg, S. Yusuf Collaborative Group on ACE Inhibitor Trials Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure JAMA 273 1995 1450 1456
4. M. Packer, M.R. Bristow, J.N. Cohn US Carvedilol Heart Failure Study Group The effect of carvedilol on morbidity and mortality in patients with chronic heart failure N Engl J Med 334 1996 1349 1355 (Pubitemid 26152713)
5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial Lancet 353 1999 9 13
6. Effect of metoprolol CR/XL in chronic heart failure Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
7. M. Packer, M.B. Fowler, and E.B. Roecker Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study Circulation 106 2002 2194 2199
8. B. Pitt, F. Zannad, W.J. Remme Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717
9. R.S. McKelvie, S. Yusuf, D. Pericak The RESOLVD Pilot Study Investigators Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study Circulation 100 1999 1032 1034
10. J.N. Cohn, G. Tognoni Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675
11. M.A. Pfeffer, K. Swedberg, and C.B. Granger Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 362 2003 759 766 (Pubitemid 37093915)
12. D.L. Keefe Clinical pharmacology of telmisartan J Clin Pharmacol 40 2000 1311
13. D. Marcelli, J. Kirchgessner, and C. Amato EuCliD (European Clinical Database): a database comparing different realities J Nephrol 14 Suppl 4 2001 S94 S100
14. J.J. McMurray, J. Ostergren, and K. Swedberg Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 2003 767 771 (Pubitemid 37093916)
15. G. Cice, L. Ferrara, A. D'Andrea, and A. Di Benedetto Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial J Am Coll Cardiol 41 2003 1438 1444
16. H. Steil, C. Amato, and C. Carioni EuCliDa medical registry Methods Inf Med 43 2004 83 88
17. F. Conte, G. Cappelli, and F. Casino Italian Registry of Dialysis and Transplantation: 19962001 experience G Ital Nefrol 21 2004 561 567
18. R. Robson, J. Collins, R. Johnson The Perfect Study Collaborative Group Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis J Nephrol 10 1997 33 40
19. K/DOQI Workgroup K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients Am J Kidney Dis 45 Suppl 3 2005 S1 S153
20. G. Cice, L. Ferrara, and A. Di Benedetto Dilated cardiomyopathy in dialysis patientsbeneficial effects of carvedilol: a double-blind, placebo-controlled trial J Am Coll Cardiol 37 2001 407 411
21. A. Takahashi, H. Takase, and T. Toriyama Candesartan, an angiotensin II tipe-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysisa randomized study Nephrol Dial Transplant 21 2006 2507 2512
22. H. Suzuki, Y. Kanno, and S. Sugahara Effect of angiotensin receptor blocker on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial Am J Kidney Dis 52 2008 501 506
23. J.B. Young, M.E. Dunlap, and M.A. Pfeffer Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials Circulation 110 2004 2618 2626
24. B. Dahlof, R.B. Devereux, S.E. Kyeldsen LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension (LIFE) study: A randomized trial against atenolol Lancet 359 2002 995 1003 (Pubitemid 34286536)
25. B. Pitt, P.A. Poole-Wilson, and R. Segal Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trialthe Losartan Health Failure Survival Study ELITE II Lancet 355 2000 1582 1587
26. F. Zannad, M. Kessler, and P. Lehert Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies Kidney Int 70 2006 1318 1324
27. Brenner BM. Brenner and Rector's The Kidney. 8th edition. Philadelphia, PA: Saunders Book Company.
28. J.G. Kelly, G.D. Doyle, M. Carmody, D.R. Glover, and W.D. Cooper Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis Br J Clin Pharmacol 26 1988 781 786
29. M. Metra, S. Nodari, and G. Parrinello Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance Am Heart J 145 2003 292 299
30. F. Tentori, W.C. Hunt, and M. Rohrscheib Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization? J Am Soc Nephrol 18 2007 2377 2384